Compugen (CGEN) to Release Earnings on Monday

Compugen (NASDAQ:CGEN) will likely be announcing its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect Compugen to announce earnings of ($0.07) per share and revenue of $1.2850 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 3, 2026 at 8:30 AM ET.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The company had revenue of $2.18 million for the quarter, compared to the consensus estimate of $1.57 million. Compugen had a return on equity of 47.72% and a net margin of 47.97%. On average, analysts expect Compugen to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Compugen Price Performance

CGEN opened at $2.28 on Monday. The stock has a market cap of $215.57 million, a PE ratio of 6.16 and a beta of 2.76. Compugen has a 52 week low of $1.29 and a 52 week high of $3.23. The business’s fifty day simple moving average is $2.31 and its 200 day simple moving average is $2.24.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in shares of Compugen by 3.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after buying an additional 51,565 shares in the last quarter. State Street Corp increased its holdings in shares of Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 14,701 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 359,785 shares in the last quarter. Two Sigma Investments LP increased its holdings in Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after buying an additional 18,929 shares in the last quarter. Finally, Marshall Wace LLP raised its position in Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after buying an additional 61,202 shares during the last quarter. 12.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CGEN shares. Wall Street Zen cut Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Lake Street Capital assumed coverage on Compugen in a research report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price for the company. Leerink Partners cut their target price on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, May 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Compugen has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.